» Articles » PMID: 36244332

Primary Malignant Brain Tumors Following Systemic Malignancies: A Population-Based Analysis

Overview
Specialties Neurology
Public Health
Date 2022 Oct 16
PMID 36244332
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several reports have described glioma following different cancers. We assessed the prevalence of primary malignant brain tumors afterward systemic malignancies in patients in the USA based on Surveillance, Epidemiology, and End Results (SEER) program data.

Methods: The detailed data of patients with primary malignant brain tumors following an initial malignant tumor outside the central nervous system were extracted from SEER. Descriptive statistics were used to analyze patient demographic and clinical characteristics. We also extracted standardized incidence ratios (SIRs) stratified by age, race, sex, history of radiation or chemotherapy, histology findings, and primary cancer site.

Results: We identified 5,212 patients diagnosed with primary malignant brain tumors following systemic malignancies. Most patients had prostate cancer, breast cancer, and skin melanoma as the primary cancer. The median duration between the first diagnosis of cancer and that of the subsequent malignant brain tumor was 53 months. Glioblastoma was the most common subsequent malignant brain tumor type. The prognosis after subsequent malignant brain tumor diagnosis was poor. The SIRs differed most by race, cancer site, and cancer type. Patients with acute lymphocytic leukemia had the highest risk of developing primary malignant brain tumors.

Conclusion: Our study provides a comprehensive analysis of clinical data and the SIRs of patients with primary malignant brain tumors afterward other systemic malignancies. Genetic relationships might play a key role in subsequent malignant brain tumor origin. Our data provide directions for future studies exploring the hidden associations between systemic malignancies and primary malignant brain tumors.

Citing Articles

Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.

Varachev V, Susova O, Mitrofanov A, Naskhletashvili D, Krasnov G, Ikonnikova A Int J Mol Sci. 2024; 25(23).

PMID: 39684714 PMC: 11641329. DOI: 10.3390/ijms252313004.


Differential gene expression analysis supports dysregulation of mitochondrial activity as a new perspective for glioblastoma's aggressiveness.

Oliveira R, Gouvea de Souza F, Bispo A, Epifane-de-Assuncao M, Cavalcante G Heliyon. 2024; 10(22):e40414.

PMID: 39641080 PMC: 11617864. DOI: 10.1016/j.heliyon.2024.e40414.


Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.

Sadowski K, Jazdzewska A, Kozlowski J, Zacny A, Lorenc T, Olejarz W Int J Mol Sci. 2024; 25(11).

PMID: 38891962 PMC: 11172387. DOI: 10.3390/ijms25115774.


Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.

Onciul R, Brehar F, Toader C, Covache-Busuioc R, Glavan L, Bratu B Curr Issues Mol Biol. 2024; 46(3):2402-2443.

PMID: 38534769 PMC: 10969338. DOI: 10.3390/cimb46030153.


Impact of prior cancer history on survival in brain malignancy: A propensity score-adjusted, population-based study.

Ur Rehman M, Faraz F, Ahmad Cheema H, Ashruf O, Raheel H, Naqvi S Cancer Rep (Hoboken). 2024; 7(2):e1984.

PMID: 38389401 PMC: 10884616. DOI: 10.1002/cnr2.1984.

References
1.
Piccirilli M, Salvati M, Bistazzoni S, Frati A, Brogna C, Giangaspero F . Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Tumori. 2005; 91(3):256-60. DOI: 10.1177/030089160509100309. View

2.
Ahmed I, Krishnamurthy S, Kakkar A, Julka P, Rath G . Primary anaplastic astrocytoma of the brain after prophylactic cranial irradiation in a case of acute lymphoblastic leukemia: Case report and review of the literature. Indian J Med Paediatr Oncol. 2014; 35(1):86-8. PMC: 4080671. DOI: 10.4103/0971-5851.133729. View

3.
Kajitani T, Kanamori M, Saito R, Watanabe Y, Suzuki H, Watanabe M . Three case reports of radiation-induced glioblastoma after complete remission of acute lymphoblastic leukemia. Brain Tumor Pathol. 2018; 35(2):114-122. DOI: 10.1007/s10014-018-0316-1. View

4.
Andersen L, Friis S, Hallas J, Ravn P, Gaist D . Hormone replacement therapy and risk of glioma: a nationwide nested case-control study. Cancer Epidemiol. 2013; 37(6):876-80. DOI: 10.1016/j.canep.2013.09.017. View

5.
Hanalioglu S, Hasanov E, Altundag K . Breast cancer and high-grade glioma: link or coincidence?. J BUON. 2015; 20(5):1378-9. View